Provectus to hold CC to discuss PV-10 development plan

|About: Provectus Biopharmaceu... (PVCT)|By:, SA News Editor

At 4 pm EDT on June 19, Provectus Biopharmaceuticals (PVCT +9.8%) will hold a conference call to present its plans for the continued development of its cancer drug candidate PV-10. Management will discuss its proposed Phase 3 clinical trial for melanoma and its progress in developing PV-10 for other cancer indications.

Management will also present its plans to monetize PV-10 and PH-10 via licensing and co-development agreements.

This was corrected on 06/12/2014 at 11:05 AM. the original item mentioned incorrect date of conference call